Estados Unidos - inglês - NLM (National Library of Medicine)

akorn - esomeprazole sodium (unii: l2c9gwq43h) (esomeprazole - unii:n3pa6559ft) - esomeprazole 40 mg in 5 ml - esomeprazole sodium for injection is indicated for the short-term treatment of gerd with ee in adults and pediatric patients 1 month to 17 years, inclusively as an alternative to oral therapy when oral esomeprazole is not possible or appropriate. esomeprazole sodium for injection is indicated for risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults. - esomeprazole sodium for injection is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria [see adverse reactions (6.2)] . - proton pump inhibitors (ppis), including esomeprazole sodium for injection, are contraindicated in patients receiving rilpivirine-containing products [see drug interactions (7)] . risk summary there are no adequate and well-controlled st

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - esomeprazole - gastro-resistant tablet - 20mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - esomeprazole - gastro-resistant tablet - 20mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

cipla eu ltd - esomeprazole - gastro-resistant tablet - 20mg

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole, quantity: 40 mg - capsule, enteric - excipient ingredients: crospovidone; glyceryl monostearate; triethyl citrate; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; purified talc; hyprolose; mannitol; sodium hydroxide; sucrose; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch - noxicid is indicated for: 1. gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (gord) 2. patients requiring nsaid therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. 3. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion 4. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori - eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole, quantity: 20 mg - capsule, enteric - excipient ingredients: glyceryl monostearate; mannitol; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; hyprolose; crospovidone; triethyl citrate; purified talc; sodium hydroxide; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate; maize starch - noxicid is indicated for: 1. gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (gord) 2. patients requiring nsaid therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. 3. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion 4. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori - eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Estados Unidos - inglês - NLM (National Library of Medicine)

r2 pharma, llc - esomeprazole strontium (unii: c5n25h3803) (esomeprazole - unii:n3pa6559ft) - esomeprazole 40 mg - 1.1 treatment of gastroesophageal reflux disease (gerd) in adults healing of erosive esophagitis esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. maintenance of healing of erosive esophagitis esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. 1.2 risk reduction of nsaid-associated gastric ulcer in adults esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for devel

Estados Unidos - inglês - NLM (National Library of Medicine)

parapro llc - esomeprazole strontium (unii: c5n25h3803) (esomeprazole - unii:n3pa6559ft) - esomeprazole 24.65 mg - 1.1 treatment of gastroesophageal reflux disease (gerd) in adults healing of erosive esophagitis esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. maintenance of healing of erosive esophagitis esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. 1.2 risk reduction of nsaid-associated gastric ulcer in adults esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for devel

Estados Unidos - inglês - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 40 - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules, usp are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules, usp may be considered.             maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules, usp are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules, usp are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. esomeprazole magnesium delayed-release capsules, usp are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid